Global Mitral Regurgitation Market Growth (Status and Outlook) 2023-2029

Global Mitral Regurgitation Market Growth (Status and Outlook) 2023-2029

Mitral regurgitation (MR) is the backflow of blood from the left ventricle into the left atrium during left ventricular systole. The mitral valve is located in the opening between the left atrium and the left ventricle. It opens to allow blood from the left atrium to fill the left ventricle. When the left ventricle contracts, the mitral valve closes so that pumped blood can only flow into the aorta. When the mitral valve is not fully closed, some blood can leak back into the left atrium. Mitral regurgitation can be divided into primary and secondary MR according to the pathogenesis. Primary mitral regurgitation is due to the pathological changes of one or more of the mitral valve leaflets, valve annulus, chordae tendineae and papillary muscles, such as degenerative disease or rheumatic disease, which cause the mitral valve to fail to close normally. Secondary mitral valve regurgitation is functional mitral valve regurgitation, which is caused by the disease of the heart itself or the valve supporting structure, such as pathological changes of the myocardium leading to pathological dilatation of the left ventricle and mitral valve annulus or Mitral regurgitation due to localized displacement of the left ventricle and subvalvular device. The current quantitative assessment of mitral valve regurgitation, the current standards of various guidelines and documents are not completely consistent, generally divided into mild, moderate and severe, this classification is relatively broad, can not well reflect the changes and manifestations before and after surgery effect of surgery. In the MitraClip system clinical trial, mitral regurgitation was divided into no (0+), mild (1+), moderate (2+), moderate to severe (3+), severe (4+), and then more This classification method is used in several clinical studies of mitral valve regurgitation interventional therapy.
LPI (LP Information)' newest research report, the “Mitral Regurgitation Industry Forecast” looks at past sales and reviews total world Mitral Regurgitation sales in 2022, providing a comprehensive analysis by region and market sector of projected Mitral Regurgitation sales for 2023 through 2029. With Mitral Regurgitation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mitral Regurgitation industry.
This Insight Report provides a comprehensive analysis of the global Mitral Regurgitation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mitral Regurgitation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mitral Regurgitation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mitral Regurgitation and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mitral Regurgitation.
The global Mitral Regurgitation market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Mitral Regurgitation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Mitral Regurgitation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Mitral Regurgitation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Mitral Regurgitation players cover Edwards Lifesciences, Abbott, CardioSolution, NeoChord, Mitralign, Medtronic, Boston Scientific, Mitralix and Shanghai Hanyu Medical Technology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Mitral Regurgitation market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Primary Mitral Regurgitation
Secondary Mitral Regurgitation
Segmentation by application
Transapical
Via Stock and Via Interstitial
Right Internal Jugular Vein
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Edwards Lifesciences
Abbott
CardioSolution
NeoChord
Mitralign
Medtronic
Boston Scientific
Mitralix
Shanghai Hanyu Medical Technology
Valgen Holding Corporation
NeoChord
CoreMedic
Babic Chord
Gore Medical
Valtech Cardio
Transcardiac
ChoRe
AVVIE
Cardiovalve
HighLife SAS
Neovasc
MitrAssist Lifesciences
Shanghai NewMed Medical
Peijia Medical
MicroPort CardioFlow Medtech

Please note: The report will take approximately 2 business days to prepare and deliver.